Heyholder
‹ Activism Filings

OSCOTECInc. Value-up Plan 2025 Progress Report: R&D Spending KRW 15.89 Billion

OSCOTECInc.· Corporate Value-up Plan

AI summary · Not investment advice

Oscotec filed its 2025 corporate value-up plan progress report, including R&D spending of KRW 15.89 billion, and is not a high-dividend company.

Key facts

Key targets
R&D investment (target: at least KRW 21.0 billion standalone by 2027) - KRW 15.89 billion in 2025 (up 66.4% year over year)R&D investment target and 2025 progress
Key targets
License-out (target: at least 5 deals by 2034) - 2 achieved: Sanofi (Dec 2025), Agios (Jun 2026)License-out target and progress
Key targets
New clinical trial (target: at least 1 by 2027) - OCT-598 Phase 1 started in Dec 2025 (achieved 2 years early)New clinical trial target and progress
Key targets
Profitability improvement (target: positive ROE by 2027) - 2025 consolidated revenue KRW 99.8 billion, operating profit KRW 52.1 billion, consolidated ROE 34.1% (achieved 2 years early)Profitability target and progress
High-dividend company
Not applicable
Plan title
Oscotec Corporate Value-up Plan Implementation Status (2025)
PBR improvement plan
Not included
Tech-growth company plan
Not included
Decision date
Nov 2, 2026Board report date
Related materials
https://oscotec.com/ko/investors/ir-materialPosted on 2026-11-04

Commentary

AI commentary · Not investment advice

What happened

Oscotec filed a progress report on its corporate value-up plan for 2025. The plan has 4 goals: R&D spending, license-out deals, new clinical trials and profitability.

In the company's terms

R&D spending was KRW 158.9 billion in 2025, up 66.4% from the prior year. The goal is at least KRW 21.0 billion on a standalone basis by 2027. For license-out deals (selling rights to its technology), the goal is 5 or more by 2034. 2 are done so far: Sanofi (December 2025) and Agios (June 2026).

What changes for shareholders

The goal for new clinical trials was at least 1 by 2027. The OCT-598 Phase 1 trial started in December 2025, 2 years early. For profitability, the goal was a positive return on equity (ROE, profit relative to shareholders' capital) by 2027. Consolidated 2025 revenue was KRW 99.8 billion and operating profit was KRW 52.1 billion. Consolidated ROE was 34.1%, also 2 years early.

The plan has no price-to-book ratio (PBR) improvement plan and no technology growth company plan. The company is not a high-dividend company. Details are on the company's investor relations page.

Comments

No comments yet

Comments from shareholders will appear here.